Metafolin vs folic acid in baby formula:
which brands use which form.

If you have been reading baby formula ingredient lists, you have probably come across the word Metafolin. And if you have googled it, you have probably found a dozen articles explaining that it is superior, natural, and bioavailable, usually on retailer websites that happen to sell the formulas containing it.

The reality is more interesting and more nuanced. Metafolin is a legitimate scientific advance. It is also a patented commercial product that formula brands pay a licensing fee to use. Both of these things are true simultaneously, and a parent trying to make an informed decision deserves both sides of the story.

What Metafolin actually is

Metafolin is the registered trademark of Merck KGaA for calcium L-5-methyltetrahydrofolate. L-5-MTHF is the biologically active form of vitamin B9 that the body actually uses for DNA synthesis, cell division, and neural tube development. It is the predominant form of folate found in breast milk.

The widespread marketing claim that Metafolin is "derived from natural sources" needs a caveat. According to the EFSA scientific opinion, calcium L-methylfolate is produced by chemical synthesis starting from folic acid. The nutrient source is not extracted from a plant. It is manufactured industrially to match the chemical structure of the folate that occurs naturally in human milk. The molecule is bioidentical; the production process is not natural.

This distinction matters because it clarifies what the value proposition actually is. Metafolin is not natural in the way honey is natural. It is a synthetic compound engineered to be chemically indistinguishable from the form your body prefers. That is a meaningful scientific achievement, just not the one the marketing suggests.

Folic acid vs methylfolate: what is the difference

Folic acid and methylfolate are both forms of vitamin B9. They differ in how the body processes them.

Folic acid is a fully oxidised synthetic compound. When consumed, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) in the liver, then converted through several additional steps before it becomes L-5-MTHF, the form the body actually uses. This conversion works, but it is not always efficient. The DHFR enzyme has relatively weak activity, and when the body receives more folic acid than it can promptly convert, some of it circulates as unmetabolised folic acid (UMFA).

Methylfolate (L-5-MTHF) skips this processing entirely. It is already in the active form, so it does not depend on liver conversion to be utilised.

The MTHFR question, honestly

Almost every article about Metafolin mentions the MTHFR gene. Most of them overstate its clinical relevance. Here is the accurate picture.

MTHFR is the enzyme that catalyses the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the form cells actually use for one-carbon methylation reactions. Two common variants of the MTHFR gene exist: C677T and A1298C. The C677T variant is the more studied of the two. People homozygous for C677T (TT genotype) have approximately 70 percent reduced enzyme activity. People heterozygous (CT) have approximately 35-40 percent reduced activity.

Prevalence varies substantially by ethnicity. According to data summarised by the American Heart Association, the homozygous (TT) form occurs in roughly 8-20 percent of people of North American, European, and Australian ancestry, is rarer in people of African ancestry (1-2 percent), and is common in Hispanic and certain Asian populations. The heterozygous (CT) form is more common, occurring in roughly 33-45 percent of most populations.

Many online sources quote a figure of "40 percent of people have an MTHFR mutation." This is technically true, in the sense that around 40 percent of some populations carry at least one copy of C677T. It is clinically misleading. A single C677T allele has modest effects on enzyme activity. The genotype that most clearly predicts impaired folate metabolism is homozygous TT, which affects a much smaller group.

In 2013, the American College of Medical Genetics issued a practice guideline concluding that MTHFR polymorphism testing should not be ordered as part of clinical evaluation for thrombophilia or recurrent pregnancy loss, citing a lack of evidence that variant status reliably predicts outcomes. The American College of Obstetricians and Gynecologists reached a similar conclusion regarding routine screening. Both positions remain the current consensus. This is important context. MTHFR variants are real. Their clinical significance for infants on formula is less established than Metafolin marketing implies.

What the clinical trial actually found

The evidence base for methylated folate in infant formula rests largely on a single randomised controlled trial: the MEFOLIN study, published in PLOS ONE in 2019.

The design was sound. 240 healthy term infants in Belgrade, Serbia, were randomised to receive formula containing either equimolar doses of L-5-MTHF or folic acid from under 28 days of age. A reference group of 120 breastfed infants was followed separately. The study was double-blind and pre-registered.

The findings were measured but meaningful. Weight gain, the primary outcome, was equivalent between the two formula groups (95% CI -2.11 to 1.68 g/d). There were no differences in tolerance or adverse events. Head circumference growth was equivalent. The formulas performed the same on the outcomes that matter most to healthy development.

Two biomarker differences did emerge. Infants fed the L-5-MTHF formula had lower mean plasma unmetabolised folic acid (0.73 vs 1.15 nmol/L, p<0.0001) and higher red cell folate (907 vs 839 nmol/L, p=0.0095). Whether either of these biochemical findings translates to meaningful clinical benefit is a separate question that the study did not answer.

A wider body of pharmacokinetic work supports the suitability case in adults. A 2010 review in Clinical Pharmacokinetics by Pietrzik and colleagues concluded that folic acid and L-5-methylfolate have comparable bioavailability at equimolar doses, and suggested two potential advantages for the methylated form: reduced masking of haematological symptoms of vitamin B12 deficiency, and reduced interaction with drugs that inhibit dihydrofolate reductase. That review is widely cited by formula retailers. It is also important to note that it was funded by Merck Eprova, the manufacturer of Metafolin. The disclosure is present in the original paper and routinely omitted in the retail citations. The findings do not become wrong because of the funding source, but the framing of the paper as independent evidence is not accurate.

Which formulas use which form

This is where the reseller articles fall short. Most of them imply that methylated folate is a general feature of EU organic formulas. It is not. As of April 2026, HiPP's cow-milk Combiotik lines are essentially the only major infant formulas on either side of the Atlantic that have made the switch from synthetic folic acid to L-methylfolate. Even HiPP's other product lines were not included in the reformulation. The table below is based on published ingredient lists on current cans.

The pattern that emerges is not what the reseller marketing suggests. This is not a story about EU organic formula being different from US formula on this dimension. With the single exception of HiPP's cow-milk Combiotik lines, every major organic and conventional infant formula on both sides of the Atlantic uses synthetic folic acid. Even HiPP's own other product lines still use folic acid. HiPP Combiotik alone has made the reformulation investment, and four and a half years later, no major competitor, not even HiPP's other lines, has followed.

Why only HiPP Combiotik made the switch

This is the structural story that the reseller blogs miss entirely. The real question is not why US brands still use folic acid. It is why almost no one, on either side of the Atlantic, has followed HiPP Combiotik's reformulation. Not even HiPP's other product lines.

The EU and US regulatory frameworks for infant formula differ. EFSA actively reviews and authorises specific nutrient sources, and the 2020 NDA Panel opinion on calcium L-methylfolate provided the regulatory pathway for any EU brand to adopt it. The FDA operates a different system. Infant formulas must meet nutrient adequacy requirements under the Infant Formula Act, but the agency does not formally evaluate or recommend specific molecular forms of each nutrient. US manufacturers choose forms based on cost, regulatory familiarity, and supply.

But the regulatory story only explains why the US lags. It does not explain why Holle, Lebenswert, Kendamil, Jovie, and Nannycare, all of which could reformulate under the same 2020 EFSA opinion that HiPP relied on, have not done so. It does not even explain why HiPP's other product lines, including Goat, HA, Comfort and Anti-Reflux, were not included in the Combiotik reformulation. The more accurate explanation is commercial. Metafolin is a single-supplier patented product from Merck. It costs more per unit than commodity folic acid. Reformulation requires reworking the vitamin premix, re-running stability testing, updating labels across every market, and absorbing a higher ingredient cost per can. HiPP made that investment in 2021 for its cow-milk Combiotik lines specifically. The decision was strategic, not a regulatory obligation, and HiPP itself limited the scope to a subset of its product portfolio. Other EU brands calculated differently, presumably because they judged the marketing upside did not justify the cost.

That is useful context for a parent interpreting the claims. The methylated folate in HiPP Combiotik is not a feature of EU organic formula certification. It is not even a feature of HiPP as a brand. It is a feature of specific HiPP product lines. The other EU organic brands, and HiPP's other product lines, are on this particular ingredient using the same synthetic folic acid as Similac.

So is Metafolin better for your baby

This is the question worth asking directly. Here is the honest answer.

For most healthy infants without MTHFR variants, the clinical evidence does not clearly show that methylated folate is superior to folic acid. Growth is equivalent. Folate adequacy is achieved with either form. The biomarker differences found in the MEFOLIN trial are real but their clinical meaning is not established.

For infants with significant MTHFR variants, particularly homozygous C677T (TT genotype), a theoretical case for methylated folate is stronger. These infants have reduced capacity to convert folic acid to the active form, so a formula providing the active form bypasses that limitation. But no trial has specifically tested outcomes in this subgroup of formula-fed infants. The case is mechanistic, not empirical.

On the unmetabolised folic acid question, the MEFOLIN trial confirmed that methylated folate produces lower plasma UMFA in infants. Whether this biomarker difference matters clinically is an open research question, not a settled one. Treating lower UMFA as a meaningful health objective goes beyond what the current evidence supports. Concern is plausible; proof of harm in healthy infants is not.

The framing we think is accurate: methylated folate is a reasonable upgrade in a category (folate nutrition) where folic acid was already adequate. For most babies it probably does not matter much. For a minority it might matter more. The benefit is real but modest, and has been marketed more aggressively than the evidence warrants.

What to check on a can

If this is a factor in your formula choice, here is what to look for on the ingredient panel.

Methylated folate appears on labels as any of these terms: "Metafolin", "L-methylfolate", "L-5-methyltetrahydrofolate", "(6S)-5-methyltetrahydrofolic acid", or "calcium L-5-methyltetrahydrofolate". All refer to the same substance.

Folic acid appears on labels simply as "folic acid" or "pteroylmonoglutamic acid". If the ingredient list shows folic acid and no methylfolate, the formula uses the synthetic form.

On a US nutrition panel, you may see "folate" and "folic acid" listed separately with different numbers. This is a regulatory artefact, not evidence of two forms. Under the 2016 FDA labelling rule, folate is declared in micrograms Dietary Folate Equivalents (DFE), a bioavailability-adjusted value calculated by multiplying the added folic acid amount by 1.7. So a can might show "Folic acid 10 mcg" and "Folate 17 mcg DFE" and those refer to the same ingredient expressed two ways. The ingredient list is the reliable place to confirm which folate form is actually used.

Important caveat. Formulations change. Stage numbers within the same brand may differ. Country-specific versions (HiPP German vs UK vs Dutch) may differ. The reliable source is always the can currently in your hand, not a blog post or a reseller site. If in doubt, verify on the manufacturer's own product page for the specific stage and region.